NCT02476786
|
Phase II |
Anastrozole
Fulvestrant
Goserelin
Tamoxifen
Exemestane
|
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score |
Recruiting |
NCT00936390
|
Phase III |
Flutamide
Goserelin
Leuprolide
Triptorelin
Bicalutamide
|
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer |
Active, not recruiting |
NCT03450109
|
Phase I |
LY01005
Goserelin
|
A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX) in Patients With Prostate Cancer |
Completed |
NCT02594072
|
Phase I |
Goserelin
|
Androgen Suppression With Stereotactic Body or External Beam Radiation Therapy (ASSERT) (ASSERT) |
Recruiting |
NCT02115282
|
Phase III |
Goserelin
Entinostat
Exemestane
|
Exemestane With or Without Entinostat in Treating Postmenopausal Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic |
Active, not recruiting |
NCT02003209
|
Phase III |
Goserelin
Pertuzumab + Trastuzumab + Carboplatin + Docetaxel
|
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer |
Active, not recruiting |
NCT02059213
|
Phase II |
Goserelin
Palbociclib
Bicalutamide
Leuprolide
|
A Phase II Study of Androgen Deprivation Therapy With or Without PD 0332991 in RB-Positive Metastatic Prostate Cancer |
Active, not recruiting |
NCT02685397
|
Phase II |
Enzalutamide
Triptorelin
Goserelin
Leuprolide
|
Management of Castration-Resistant Prostate Cancer With Oligometastases |
Recruiting |
NCT01723774
|
Phase II |
Palbociclib
Anastrozole
Goserelin
|
PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer |
Recruiting |
NCT00541047
|
Phase III |
Leuprolide
Goserelin
Bicalutamide
|
Radiation Therapy and Androgen Deprivation Therapy in Treating Patients Who Have Undergone Surgery for Prostate Cancer (RADICALS) |
Active, not recruiting |
NCT02023463
|
Phase I |
Goserelin
Enzalutamide
Leuprolide
|
Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer |
Active, not recruiting |
NCT02586675
|
Phase I |
Goserelin
LEE001 + Tamoxifen
|
TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer |
Active, not recruiting |
NCT01674140
|
Phase III |
Goserelin
Anastrozole
Letrozole
Leuprolide
Everolimus
Tamoxifen
Exemestane
|
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer |
Recruiting |
NCT03007979
|
Phase II |
Goserelin
Fulvestrant + Palbociclib
Palbociclib + Letrozole
|
Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer |
Active, not recruiting |
NCT02058706
|
Phase II |
Goserelin
Bicalutamide
Enzalutamide
Leuprolide
|
LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer |
Active, not recruiting |
NCT02278185
|
Phase II |
Goserelin
Degarelix
Histrelin acetate
Triptorelin
Leuprolide
Enzalutamide
|
Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer |
Recruiting |
NCT02346253
|
Phase Ib/II |
Leuprolide
Triptorelin
Degarelix
Bicalutamide
Goserelin
|
High-Dose Brachytherapy in Treating Patients With Prostate Cancer |
Recruiting |
NCT02907918
|
Phase II |
Goserelin
Letrozole + Palbociclib + Trastuzumab
|
Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer (PALTAN) |
Recruiting |
NCT02626507
|
Phase I |
Palbociclib
Gedatolisib
Goserelin
Fulvestrant
|
Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer |
Recruiting |
NCT01786265
|
Phase II |
Goserelin
Degarelix
Abiraterone
Prednisone
Leuprolide
|
Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone |
Active, not recruiting |
NCT02472275
|
Phase I |
Leuprolide
Pexidartinib
Goserelin
Degarelix
|
PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer |
Suspended |
NCT02278120
|
Phase III |
Tamoxifen
Letrozole
Ribociclib
Goserelin
Anastrozole
|
Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer |
Active, not recruiting |
NCT03279250
|
Phase II |
Goserelin
Triptorelin
Abiraterone + Apalutamide + Prednisone
Leuprolide
Apalutamide
|
Effects of Apalutamide Plus LHRH Agonist or Apalutamide Plus Abiraterone Acetate Plus LHRH Agonist for Six Months for Prostate Cancer Patients at High Risk for Recurrence |
Recruiting |
NCT02366494
|
Phase I |
Leuprolide
Goserelin
Triptorelin
Bicalutamide
Docetaxel
|
Micro RNAs to Predict Response to Androgen Deprivation Therapy |
Recruiting |
NCT02430480
|
Phase II |
Goserelin
|
Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer |
Recruiting |
NCT02204098
|
Phase I |
Letrozole
Anastrozole
Goserelin
Exemestane
Tamoxifen
|
Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy |
Recruiting |
NCT00002651
|
Phase III |
Bicalutamide
Goserelin
|
Hormone Therapy in Treating Men With Stage IV Prostate Cancer |
Completed |
NCT01717053
|
Phase II |
Leuprolide
Abiraterone
Prednisone
Goserelin
|
Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer |
Active, not recruiting |
NCT03678025
|
Phase III |
Docetaxel
nilutamide
Triptorelin
Bicalutamide
Leuprolide
Degarelix
Goserelin
Flutamide
Prednisone
Abiraterone
Histrelin acetate
|
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer |
Recruiting |
NCT02064036
|
Phase I |
Bicalutamide
Goserelin
Leuprolide
|
Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate |
Recruiting |
NCT03511196
|
Phase I |
Abiraterone + Prednisone
Leuprolide
Goserelin
Triptorelin
|
Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer |
Recruiting |